Skip to main content
Fig. 3 | Molecular Neurodegeneration

Fig. 3

From: A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy

Fig. 3

Cellular uptake of neurosin-apoB in the CNS following systemic delivery of the lentivector to MBP-a-syn tg mice. Non-tg and MBP-α-syn tg received a single i.p. injection with either LV-Control or LV-NR-R80Q-apoB. Three months later mice were sacrificed and brains were analyzed by double immunofluorescence and confocal microscopy for analysis of the co-localization of neurosin with cellular markers. Dotted box to the left depicts the image field zoomed represented under detail. a Double immunolabeling for V5 tag to identify neurosin (red) and the neuronal marker NeuN (green). Co-immunolabeling is represented by signal in yellow. b Computer aided image analysis of the % of NeuN cells displaying neurosin (V5). c Double immunolabeling for V5 tag to identify neurosin (red) and the microglial cell marker Iba-1 (green). d Computer aided image analysis of the % of microglial cells displaying neurosin (V5) immunostaining. e Double immunolabeling for V5 tag to identify neurosin (red) and the astrocytic marker GFAP (green). f Computer aided image analysis of the % of astroglial cells displaying neurosin (V5) immunostaining. g Double immunolabeling for V5 tag to identify neurosin (red) and the oligodendrocyte marker Olig-2 (green). h Computer aided image analysis of the % of oligodendroglial cells displaying neurosin (V5) immunostaining. All images are from the striatum. n = 10 mice per group 9–10 m/o at the end of the treatment. * - indicates one way ANOVA post hoc Dunnett’s p < 0.05 compared to non-tg mice that received LV-Control. Scale bar = 10 μm, detail = 20 μm

Back to article page
\